• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

单次或多次剂量 0.25%洛替拉纳滴眼液在荷兰兔的眼部和全身药代动力学。

Ocular and Systemic Pharmacokinetics of Lotilaner Ophthalmic Solution, 0.25%, Following a Single Dose or Repeated Doses in Dutch-Belted Rabbits.

机构信息

Xyzagen, Pittsboro, North Carolina, USA.

Virginia Eye Consultants, Norfolk, Virginia, USA.

出版信息

J Ocul Pharmacol Ther. 2024 Nov;40(9):588-595. doi: 10.1089/jop.2024.0074. Epub 2024 Aug 16.

DOI:10.1089/jop.2024.0074
PMID:39150371
Abstract

To evaluate the ocular and systemic pharmacokinetics of lotilaner ophthalmic solution, 0.25%, following bilateral topical ocular administration of single and repeated doses in rabbits. Dutch-belted rabbits ( = 34) were administered lotilaner ophthalmic solution, 0.25%, eye drops, either in a single bilateral dose (Group 1) or twice a day bilaterally for 7 days and once on Day 8 (Group 2). The pharmacokinetics and tissue distribution levels of lotilaner were assessed following the single dose in Group 1 and the last dose in Group 2. The drug levels were examined in various ocular tissues and whole blood. The maximal concentration of the drug (Cmax), time to maximal concentration, the terminal phase elimination half-life, the area under the concentration-time curve (AUC), and total clearance of the drug were determined. In the eyelid margins, lotilaner exhibited the highest observed concentrations at 0.25 hour (h), presenting a mean Cmax of 14,600 ng/mL in Group 1 and 20,100 ng/mL in Group 2. The highest AUC was in the eyelid margin at 242,000 h×ng/mL in Group 1 and 535,000 h×ng/mL in Group 2. In the eyelid margin, the observed clearance rate (0.634 mL/h in single dose, 0.288 mL/h in repeat dose) was the slowest among all ocular tissues in both groups, with the longest half-life of 152 h (∼6.3 days) observed in the repeat dose group. Lotilaner ophthalmic solution, 0.25%, demonstrated rapid ocular tissue absorption into the eyelid margin tissue with a long half-life of almost a week. No adverse effects were observed following topical ocular administration in Dutch-belted rabbits.

摘要

为了评估倍硫磷眼用溶液 0.25%在单次和重复双侧眼部给药后兔眼和全身的药代动力学,给 34 只荷兰兔双侧眼部滴注倍硫磷眼用溶液 0.25%,单次剂量(第 1 组)或每天 2 次双侧眼部滴注共 7 天,第 8 天单次滴注(第 2 组)。第 1 组单次剂量和第 2 组末次剂量后评估倍硫磷的药代动力学和组织分布水平。检测各种眼部组织和全血中的药物浓度。确定药物的最大浓度(Cmax)、达峰时间(Tmax)、末端相消除半衰期(t1/2)、浓度-时间曲线下面积(AUC)和药物总清除率。在眼睑边缘,第 1 组在 0.25 小时(h)观察到最高药物浓度,Cmax 平均值为 14600ng/mL,第 2 组为 20100ng/mL。第 1 组眼睑边缘的 AUC 最高为 242000h×ng/mL,第 2 组为 535000h×ng/mL。在眼睑边缘,观察到的清除率(单次剂量为 0.634mL/h,重复剂量为 0.288mL/h)在两组所有眼部组织中最慢,重复剂量组观察到最长半衰期为 152h(约 6.3 天)。倍硫磷眼用溶液 0.25%在兔眼快速吸收到眼睑边缘组织,半衰期接近一周。在荷兰兔眼部局部应用后未观察到不良反应。

相似文献

1
Ocular and Systemic Pharmacokinetics of Lotilaner Ophthalmic Solution, 0.25%, Following a Single Dose or Repeated Doses in Dutch-Belted Rabbits.单次或多次剂量 0.25%洛替拉纳滴眼液在荷兰兔的眼部和全身药代动力学。
J Ocul Pharmacol Ther. 2024 Nov;40(9):588-595. doi: 10.1089/jop.2024.0074. Epub 2024 Aug 16.
2
Lotilaner Ophthalmic Solution 0.25% for Demodex Blepharitis: Randomized, Vehicle-Controlled, Multicenter, Phase 3 Trial (Saturn-2).Lotilaner 眼科溶液 0.25%用于治疗蠕形螨睑缘炎:随机、对照、多中心、3 期临床试验(Saturn-2)。
Ophthalmology. 2023 Oct;130(10):1015-1023. doi: 10.1016/j.ophtha.2023.05.030. Epub 2023 Jun 5.
3
Collarette Elimination and Mite Eradication with Topical Lotilaner Ophthalmic Solution, 0.25.应用 0.25% 托拉菌素滴眼液进行颈圈消除和螨类根除。
J Ocul Pharmacol Ther. 2021 Oct;37(8):479-484. doi: 10.1089/jop.2021.0011. Epub 2021 Aug 20.
4
Safety and efficacy of lotilaner ophthalmic solution, 0.25% for the treatment of blepharitis due to demodex infestation: A randomized, controlled, double-masked clinical trial.Lotilaner 眼科溶液 0.25%治疗蠕形螨感染性睑缘炎的安全性和有效性:一项随机、对照、双盲临床试验。
Cont Lens Anterior Eye. 2022 Aug;45(4):101492. doi: 10.1016/j.clae.2021.101492. Epub 2021 Jul 28.
5
Efficacy and Safety of Lotilaner Ophthalmic Solution 0.25% for the Treatment of Demodex Blepharitis: A Meta-Analysis of Randomized Controlled Trials.Lotilaner 眼科溶液 0.25% 治疗蠕形螨性睑缘炎的疗效和安全性:一项随机对照试验的荟萃分析。
Cont Lens Anterior Eye. 2024 Jun;47(3):102148. doi: 10.1016/j.clae.2024.102148. Epub 2024 Mar 21.
6
Treatment of Blepharitis: A Prospective, Randomized, Controlled, Double-Masked Clinical Trial Comparing Topical Lotilaner Ophthalmic Solution, 0.25% Eyedrops to Vehicle.睑缘炎治疗:一项比较局部应用 0.25%托拉菌素滴眼液与赋形剂的前瞻性、随机、对照、双盲临床试验。
Ocul Immunol Inflamm. 2023 Oct;31(8):1653-1661. doi: 10.1080/09273948.2022.2093755. Epub 2022 Aug 1.
7
Long-Term Outcomes of 6-Week Treatment of Lotilaner Ophthalmic Solution, 0.25%, for Demodex Blepharitis: A Noninterventional Extension Study.为期 6 周的 0.25%洛替拉纳滴眼液治疗蠕形螨性睑缘炎的长期疗效:一项非干预性扩展研究。
Cornea. 2024 Nov 1;43(11):1368-1374. doi: 10.1097/ICO.0000000000003484. Epub 2024 Feb 9.
8
Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans.贝西沙星对兔、猴和人进行局部给药后的眼药代动力学。
J Ocul Pharmacol Ther. 2009 Aug;25(4):335-44. doi: 10.1089/jop.2008.0116.
9
Ocular Distribution of Cyclosporine Following Topical Administration of OTX-101 in New Zealand White Rabbits.OTX-101 经眼部给药后新西兰白兔体内的环孢素分布情况。
J Ocul Pharmacol Ther. 2019 Sep;35(7):395-402. doi: 10.1089/jop.2018.0106. Epub 2019 Aug 6.
10
Ocular pharmacokinetics comparison between 0.2% olopatadine and 0.77% olopatadine hydrochloride ophthalmic solutions administered to male New Zealand white rabbits.给予雄性新西兰白兔0.2%奥洛他定和0.77%盐酸奥洛他定滴眼液后的眼药代动力学比较。
J Ocul Pharmacol Ther. 2015 May;31(4):204-10. doi: 10.1089/jop.2014.0140. Epub 2015 Mar 16.